Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(2):91; doi:10.1093/jnci/97.2.91
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Prevention Study Halted Amid Concerns About Celebrex

The National Cancer Institute has halted a large colorectal cancer prevention trial after an analysis by the trial's data safety and monitoring board found that participants taking the drug celecoxib (Celebrex) had an increased risk of major cardiovascular events compared with those taking a placebo.

Celecoxib is a COX-2 inhibitor that is approved by the U.S. Food and Drug Administration for the treatment of osteoarthritis, rheumatoid arthritis, and familial adenomatous polyposis. The . . . [Full Text of this Article]

Colonoscopy the Most Accurate Method for Colon Cancer Detection, Study Finds

Iressa Fails to Show Survival Benefit in Lung Cancer Trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?